Your browser doesn't support javascript.
loading
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects.
Kawase, Katsushige; Kawashima, Shusuke; Nagasaki, Joji; Inozume, Takashi; Tanji, Etsuko; Kawazu, Masahito; Hanazawa, Toyoyuki; Togashi, Yosuke.
  • Kawase K; Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
  • Kawashima S; Department of Otorhinolaryngology/Head & Neck Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Nagasaki J; Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
  • Inozume T; Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Tanji E; Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
  • Kawazu M; Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
  • Hanazawa T; Division of Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan.
  • Togashi Y; Department of Dermatology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Cancer Immunol Res ; 11(7): 895-908, 2023 07 05.
Article en En | MEDLINE | ID: mdl-37062030
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias de Cabeza y Cuello Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Inhibidores de Puntos de Control Inmunológico / Neoplasias de Cabeza y Cuello Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Año: 2023 Tipo del documento: Article